Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar)
Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia
Sponsor: Janssen-Cilag, S.A.
Terminated
Insufficient enrollment (Terminated due to lack of patient recruitment)
Other terminated trials from Janssen-Cilag, S.A.
- Psoriasis · Phase PHASE4 · Jul 2023
- Crohn Disease · Apr 2022
- Prostatic Neoplasms · Feb 2017
- Alzheimer Disease · Phase PHASE4 · Jun 2011
- Heart Failure · Phase PHASE3 · Sep 2009
More terminations from Janssen-Cilag, S.A.
Other Rheumatoid Arthritis trials with similar outcome
Listed as NCT02414984, this observational or N/A phase trial focuses on Rheumatoid Arthritis and remains terminated or withdrawn. Sponsored by Janssen-Cilag, S.A., it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Terminated
-
Sep 2025 — Nov 2025 [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Terminated NA
Status: Recruiting → Terminated · Phase: PHASE4 → NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen-Cilag, S.A.
For direct contact, visit the study record on ClinicalTrials.gov .